Journal article
E. Ricciotti, S. Tang, Antonijo Mrcela, U. S. Das, R. Lordan, Robin Joshi, Soumita Ghosh, Justin Aoyama, Ryan McConnell, Jianing Yang, Gregory R Grant, Garret A. FitzGerald
bioRxiv, 2024
bioRxiv, 2024
Semantic Scholar
DOI
PubMedCentral
PubMed
Cite
Cite
APA
Click to copy
Ricciotti, E., Tang, S., Mrcela, A., Das, U. S., Lordan, R., Joshi, R., … FitzGerald, G. A. (2024). Disruption of the PGE2 synthesis / response pathway restrains atherogenesis in programmed cell death-1 (Pd-1) deficient hyperlipidemic mice. BioRxiv.
Chicago/Turabian
Click to copy
Ricciotti, E., S. Tang, Antonijo Mrcela, U. S. Das, R. Lordan, Robin Joshi, Soumita Ghosh, et al. “Disruption of the PGE2 Synthesis / Response Pathway Restrains Atherogenesis in Programmed Cell Death-1 (Pd-1) Deficient Hyperlipidemic Mice.” bioRxiv (2024).
MLA
Click to copy
Ricciotti, E., et al. “Disruption of the PGE2 Synthesis / Response Pathway Restrains Atherogenesis in Programmed Cell Death-1 (Pd-1) Deficient Hyperlipidemic Mice.” BioRxiv, 2024.
BibTeX Click to copy
@article{e2024a,
title = {Disruption of the PGE2 synthesis / response pathway restrains atherogenesis in programmed cell death-1 (Pd-1) deficient hyperlipidemic mice},
year = {2024},
journal = {bioRxiv},
author = {Ricciotti, E. and Tang, S. and Mrcela, Antonijo and Das, U. S. and Lordan, R. and Joshi, Robin and Ghosh, Soumita and Aoyama, Justin and McConnell, Ryan and Yang, Jianing and Grant, Gregory R and FitzGerald, Garret A.}
}
Abstract
Immune checkpoint inhibitors (ICIs) that target programmed cell death 1 (PD-1) have revolutionized cancer treatment by enabling the restoration of suppressed T-cell cytotoxic responses. However, resistance to single-agent ICIs limits their clinical utility. Combinatorial strategies enhance their antitumor effects, but may also enhance the risk of immune related adverse effects of ICIs. Prostaglandin (PG) E2, formed by the sequential action of the cyclooxygenase (COX) and microsomal PGE synthase (mPGES-1) enzymes, acting via its E prostanoid (EP) receptors, EPr2 and EPr4, promotes lymphocyte exhaustion, revealing an additional target for ICIs. Thus, COX inhibitors and EPr4 antagonists are currently being combined with ICIs potentially to enhance antitumor efficacy in clinical trials. However, given the cardiovascular (CV) toxicity of COX inhibitors, such combinations may increase the risk particularly of CV AEs. Here, we compared the impact of distinct approaches to disruption of the PGE2 synthesis /response pathway – global or myeloid cell specific depletion of mPges-1 or global depletion of Epr4 – on the accelerated atherogenesis in Pd-1 deficient hyperlipidemic (Ldlr-/-) mice. All strategies restrained the atherogenesis. While depletion of mPGES-1 suppresses PGE2 biosynthesis, reflected by its major urinary metabolite, PGE2 biosynthesis was increased in mice lacking EPr4, consistent with enhanced expression of aortic Cox-1 and mPges-1. Deletions of mPges-1 and Epr4 differed in their effects on immune cell populations in atherosclerotic plaques; the former reduced neutrophil infiltration, while the latter restrained macrophages and increased the infiltration of T-cells. Consistent with these findings, chemotaxis by bone-marrow derived macrophages from Epr4-/- mice was impaired. Epr4 depletion also resulted in extramedullary lymphoid hematopoiesis and inhibition of lipoprotein lipase activity (LPL) with coincident spelenomegaly, leukocytosis and dyslipidemia. Targeting either mPGES-1 or EPr4 may restrain lymphocyte exhaustion while mitigating CV irAEs consequent to PD-1 blockade.
